Karl V. Ebner, Ph.D., D.A.B.T.
· Certified Toxicologist, Diplomate American Board of Toxicology. Committed to resolving forensic issues through toxicology and pharmacology principles. Background: forensic & clinical toxicology, forensic consulting, methods research and development, in vitro diagnostic (IVD) design review, quality system regulations, vaccine R&D, and biochemical toxicology. Developed in vivo animal models with diagnostic tests for Reye’s Syndrome, Alzheimer’s Disease, and organophosphate delayed neurotoxicity.
· KETox Forensic Toxicology Consulting, Okemos, MI 2001-2007
· Consults: TASA, and Speckin Forensic Labs.
· Expert reports, depositions, and opinions for both prosecution and defense concerning: 1) blood & breath alcohol concentrations, and instrument operation and performance by DataMaster, Alco-Sensor II & III, and GC; 2) drugs, drugs of abuse, and drug-alcohol interaction(s); 3) under the influence, culpability, maladaptive behavior, and nonconsensual sex; and 4) worker safety, wrongful deaths and disease etiology.
· Facilitated FEMA forensic facility restoration in Orleans Parish after hurricane Katrina.
· Forensic Toxicologist Toledo Metro Drug Unit 1972-1974
Metro Drug Unit for Monroe, MI, Toledo & Bowling Green, OH, and established drugs and drugs of abuse screen for U.S. Air Force.
· Forensic & Clinical Toxicology, Ohio State University 1974-1979
Forensics, toxology, pharmacology and clinical consultations to doctors for overdoses, therapeutic monitoring, & cause of death thru pharmcokinetics & pharmcodynamics.
· Professional Team Member, Senior Scientist, Project & Team Leader 2000-2006
ABBOTT LABORATORIES, Abbott Park, Illinois
Upgraded quality control and assurance in Design Reviews of IVDs for HIV-1/2, HTLV-I/II, hepatitis B, uterine and breast cancers, toxoplasmosis, rubella, drug monitoring, controlled substances and reference selection plans.
· Scientist & Unit Chief Michigan Public Health & BIOPORT Corp., 1989-2000
· Improved anthrax, pertussis and tetanus vaccines recovery, safety, efficacy and purity.
· Implemented and trained chemical hygiene plan and blood borne pathogen standard.
· Chaired Lab Safety and Chemical Hygiene Committee.
· Scientific Advisory Committee for Michigan Agent Orange Commission.
· Project leader and Postdoctoral Research Associate 1983-1989
Michigan State Univ. Pesticide Research Center & Toxicology & Pharmacology Dept.,
East Lansing, Michigan.
Determined toxic mechanism for dioxin (e.g., Agent Orange) & dioxin like compounds (e.g., PCBs, PBBs) to induce wasting, cachexia, diabetes, and inflammation as the chemical model for Reye’s Syndrome.
· Neurotoxicology 1982
University of Michigan, Environmental & Industrial Toxicology, Ann Arbor, Michigan
· Enzymology 1979 - 1981
Serveo Ochoa Instituto de Investigaciones Citologicas, Valencia, Spain
· OHIO STATE UNIVERSITY, Columbus, Ohio
Ph.D. Pharmacology, 1979
B.Sc. Biochemistry, 1970
· Diplomate of American Board of Toxicology 1997 to present
· Society of Toxicology, Full Member 1992 to present.
· American Assoc. for the Advancement of Science 1978 to present
· Toxicokinetics and Physiologically-Based Pharmacokinetic 2000
in Toxicology and Risk Assessment
· Antibodies as Reagents to Evaluate Toxicant-Mediated 2000
Signal Transduction Pathways
· Metabonomics – A New Approach to Drug Toxicity Screening 2000
Using NMR Spectroscopy, Pattern Recognition and Expert Systems
· Adrenal Gland: Mechanisms of Toxicity and Endocrine Disruption 2004
EXPERT DEPOSITIONS and REPORTS
· Ebner, K. 2007. Deposition on failure of simulator control chart data delineated in MSP BrAC DataMaster Manual to substantiate accuracy and precision as required by federal regulations (scheduled Oct. 2007).
· Ebner, K. 2007. Expert deposition resolving drug interactions impacting diabetic lactic acidemia without ketogenesis vs culpability of DUI of alcohol (9/6/07).
· Ebner, K. 2007. Expert authority on DataMaster operation and performance. Deposition that dismissed DataMaster BAC results due to quality assurance failure of historical simulator control data (7/19/07).
· Ebner, K. 2007. Expert deposition on discrepancies between DataMaster BrAC determination vs. BAC with ethanol dose, metabolism and elimination (6/24/07).
· Ebner, K. 2007. Resolution of consensual sex under the influence of antidepressant, Wellbutrin (Bupropion), and alcohol. (5/1/07, consult)
· Ebner, K. 2007. Resolution of defendant’s gas chromatographic BAC measurement (0.34) vs. defendant’s sobriety evaluation and quality assurance. (4/25/07, consult)
· Ebner, K. 2007. Impact of coumadin therapy on bruising injuries with assault and battery. Deposition pending.
· Ebner, K. 2007. OUI of drug(s) and resolution of confounding influences between controlled substances vs. medical treatments with: 1) antiinflammatory prednisone for rheumatoid arthritis, inflammatory bowel disease, and nephrotic syndrome; 2) analgesics Fiorinal (`Codeine-Aspirin-butalbital-caffeine) and propoxyphene napsylate; 3) muscle relaxant and sedative Soma + meprobamate; 4) anti-hypertensive lisinopril; 5) diuretics Spironolactone + furosemide and potassium supplements; and 6) gastric acid reflux treatments with Ranitidine and Sucralfate, respectively. (4/19/07)
· Ebner, K. 2007. Resolved culpability, hehavioral influences, and interactions between BAC and therapeutic interventions for diabetes (Glucophage/metformin), hypertension (felodipine), allergies (Claritin), pain (opiate analgesics), depression (Welburtin & metabolite), and sedatiion (Xanax). (4/25/07).
· Ebner, K. 2007. Resolved impact on memory recall by interactions between BAC, opiate analgesics (Hydrocodone), and hypothyroidism. Deposition and report (5/1/07).
· Ebner, K. 2007. BrAC determinations by DataMaster vs. Alco-Sensor III and false positive BAC without depravation period. (3/25/07).
· Ebner, K. 2007. DataMasterBlood alcohol elevation and prolonged duration in combination with Verapamil heart medication. Deposition. (4/5/07)
· Ebner, K. 2007. False positive cocaine/benzoylecgonine immunocompetitive assay interpretation (e.g., Rapid Drug Screen, Monitect) without confirmation testing by GC-MS. Deposition (5/11/07).
· Ebner, K. 2007. Operating under the influence and sleep driving in a bipolar individual on schedule IV Ativan and Xanax and sedative interactions during redistribution phase with valproic acid, bupropion, tramadal and their active metabolites. (3/9/07)
· Ebner, K. 2006. Nonconsensual sex and under the inlfuence of marijuana, cocaine, Soma and Ambien. (2/27/06).
· Ebner, K. 2006. Cocaine sample uniformity differences between a large seized cache vs. smaller client’s sample. Deposition (5/1/06)
· Ebner, K. 2006. Resolution of a coincidental Type 2 diabetes onset in an obese woman with familial and ethnic diabetic predisposition following an excessive dose of the rheumatoid arthritic drug, Enbrel (anti-tumor necrosis factor a). (5/6/06)
· Ebner, K. 2006. Under the influence of marijuana and detection of inactive metabolite, THCCOOH, in an electrocuted worker without ocular petechiae at autopsy. (3/9/06)
· Ebner, K. 2005. Unlawful death determination of a severely retarded patient by an overdose of antiseizure medicine, carbamazepine, based on pharmacokinetics, blood concentration, and the active (10,11-epoxide) metabolite at the time of death. (10/21/05)
PUBLICATIONS and PROFESSIONAL REVIEW
· Ebner, K. 2007. Neurtoxicology Chapter Review, American Industrial Hygiene Association.
· Ebner, K. 2007. Hepatic Toxicology Chapter Review, American Industrial Hygiene Association.
· Ebner, K. 2004. Aroclor 1254 Chemical Model for Reye’s Syndrome. (Abstr. #1193). Society of Toxicology Annual Meeting. Baltimore, MD.
· Ebner, K. 2005. Aroclor 1254 Chemical Model for Reye’s Syndrome, Mixture Toxicology (Abstr #20) Symposium. Atlanta, GA. And Linthicum, MD (2006).
· Ebner, K. 2006. Aroclor 1254 Chemical Model for Reye’s Syndrome, 2nd International Conference on Bioindicators. Linthicum, MD (2006).
· Ebner, K., Matsumura, F., Enan, E. and Olsen, H. 1993. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters pancreatic membrane tyrosine phosphorylation following acute treatment. J Biochem Toxicology 8(2), 71-81.
· Ebner, K. and Couri, D. 1988. Aroclor 1254 treatment and fasting influences on rat liver mitochondrial citrulline synthesis with ADP and ATP. Toxicol. Appl. Pharmacol. 96, 75-84.
· Ebner, K., Brewster, D.W., AND Matsumura, F. 1988. Effects of 2,3,7,8-tetrachlorodibenzo-?-dioxin on serum insulin and glucose levels in the rabbit. J. Environ. Sci. Health B23, 427-38.
· Madhukar, B.V., Ebner, K., Matsumura, F., Bombick, D.W., Brewster, D.W., and Kawamoto, T. 1988. 2,3,7,8-Tetrachlorodibenzo-?-dioxin causes an increase in protein kinase associated with EGF receptor in the hepatic plasma membrane. J. Biochem. Toxicology 3, 261-77.
· Ebner, K. and Braselton, W.E. 1987. Structural and chemical requirements for the hydroxylated polychlorinated biphenyls to uncouple rat liver mitochondria and the potentiation of uncoupling with Aroclor 1254. Chemical-Biological Interactions 63, 139-155.
· Ebner, K. and Braselton, W.E. 1987. Permeability changes in hepatic mitochondria and altered glucose and urea metabolism in Aroclor 1254 treated rats. J. Toxicol. Environ. Hlth. 22, 45-62.
· Ebner, K., Bergen, W.G., and Braselton, W.E. 1987. Nitrogen deficits in Aroclor 1254 treated rats. Fund. Appl. Toxicol. 8, 89-96.
· Hledin-Branatowska, M. Ebner, K. and Mayor, G. 1986. In vivo and in vitro effects of aluminum on rat liver mitochondrial funtions. Biological Trace Element Research 10, 235-42.
· Ebner, K, 1983. Fluorescent probe study with 1-anilino-8-naphthalene sulfonate on acetylglutamate activation, ATP binding and conformation changes of rat liver carbamoylphosphate synthase. Biochim. Biophys. Acta 746, 87-96.
· Ebner, K, 1983. Stoichiometric trapping of the putative carboxyphosphate on rat liver carbamoylphospahte synthase (ammonia) and cofactor influences. Poster FASEB, St. Louis, MO.
· Couri, D., Ebner, K., and Liss, L., 1980. Determination of aluminum in biological samples. Neurotoxicology 1, 17-24.
· Liss, L., Ebner, K. and Couri, D. 1979. Neurofibrillary tangles induced by a sclerosing angioma. Hum. Pathol. 1, 104-108.
|Dr. Karl Ebner||Email Karl|